Mitochondrial metabolism provides precursors to build macromolecules in growing cancer cells 1,2 . In normally functioning tumour cell mitochondria, oxidative metabolism of glucose-and glutamine-derived carbon produces citrate and acetyl-coenzyme A for lipid synthesis, which is required for tumorigenesis 3 . Yet some tumours harbour mutations in the citric acid cycle (CAC) or electron transport chain (ETC) that disable normal oxidative mitochondrial function 4-7 , and it is unknown how cells from such tumours generate precursors for macromolecular synthesis. Here we show that tumour cells with defective mitochondria use glutamine-dependent reductive carboxylation rather than oxidative metabolism as the major pathway of citrate formation. This pathway uses mitochondrial and cytosolic isoforms of NADP 1 / NADPH-dependent isocitrate dehydrogenase, and subsequent metabolism of glutamine-derived citrate provides both the acetylcoenzyme A for lipid synthesis and the four-carbon intermediates needed to produce the remaining CAC metabolites and related macromolecular precursors. This reductive, glutamine-dependent pathway is the dominant mode of metabolism in rapidly growing malignant cells containing mutations in complex I or complex III of the ETC, in patient-derived renal carcinoma cells with mutations in fumarate hydratase, and in cells with normal mitochondria subjected to acute pharmacological ETC inhibition. Our findings reveal the novel induction of a versatile glutamine-dependent pathway that reverses many of the reactions of the canonical CAC, supports tumour cell growth, and explains how cells generate pools of CAC intermediates in the face of impaired mitochondrial metabolism.
Mitochondrial metabolism provides precursors to build macromolecules in growing cancer cells 1, 2 . In normally functioning tumour cell mitochondria, oxidative metabolism of glucose-and glutamine-derived carbon produces citrate and acetyl-coenzyme A for lipid synthesis, which is required for tumorigenesis 3 . Yet some tumours harbour mutations in the citric acid cycle (CAC) or electron transport chain (ETC) that disable normal oxidative mitochondrial function [4] [5] [6] [7] , and it is unknown how cells from such tumours generate precursors for macromolecular synthesis. Here we show that tumour cells with defective mitochondria use glutamine-dependent reductive carboxylation rather than oxidative metabolism as the major pathway of citrate formation. This pathway uses mitochondrial and cytosolic isoforms of NADP 1 / NADPH-dependent isocitrate dehydrogenase, and subsequent metabolism of glutamine-derived citrate provides both the acetylcoenzyme A for lipid synthesis and the four-carbon intermediates needed to produce the remaining CAC metabolites and related macromolecular precursors. This reductive, glutamine-dependent pathway is the dominant mode of metabolism in rapidly growing malignant cells containing mutations in complex I or complex III of the ETC, in patient-derived renal carcinoma cells with mutations in fumarate hydratase, and in cells with normal mitochondria subjected to acute pharmacological ETC inhibition. Our findings reveal the novel induction of a versatile glutamine-dependent pathway that reverses many of the reactions of the canonical CAC, supports tumour cell growth, and explains how cells generate pools of CAC intermediates in the face of impaired mitochondrial metabolism.
We first studied the metabolism of isogenic 143B human osteosarcoma cells that contained or lacked a loss-of-function mutation in ETC complex III (cytochrome b-c1 complex). These cell lines were generated by depleting 143B mitochondrial DNA (mtDNA) and repopulating with either wild-type mtDNA or mtDNA containing a frameshift mutation in the gene encoding cytochrome b (CYTB: also known as MT-CYB), an essential complex III component 8 . Despite lack of respiration and complex III function in the mutants 8 , both wild-type (WT 143B) and CYTBmutant (CYTB 143B) cells form colonies in soft agar 9 and proliferate at comparable rates ( Supplementary Fig. 1a ), making these cells a good model in which to study growth during mitochondrial dysfunction. Both cell lines had detectable CAC intermediates, although citrate was less abundant and succinate was significantly more abundant in the CYTB 143B cells ( Supplementary Fig. 1b ). As expected for cells with defective oxidative phosphorylation, CYTB 143B cells had higher glucose consumption and lactate production than WT 143B cells, indicating a metabolic shift towards aerobic glycolysis ( Fig. 1a ). To determine the effects of CYTB mutation on the metabolic fates of glucose, we cultured both cell lines in medium containing D[U-13 C]glucose (here U indicates uniformly labelled) and measured 13 C enrichment of intracellular metabolites by mass spectrometry. In WT 143B cells, most citrate molecules contained glucose-derived 13 C (Fig. 1b ). Citrate m12 (citrate containing two additional mass units from 13 oxaloacetate (OAA). Processing of citrate m12 around one turn of the CAC produces citrate m14 ( Supplementary Fig. 2 ). In CYTB 143B cells, most citrate contained no glucose carbon (m10), indicating suppressed PDH contribution to acetyl-CoA ( Fig. 1b ). Fumarate and malate m12 were also decreased ( Supplementary Fig. 1c, d ).
Glutamine is a major respiratory substrate in cancer cells, providing energy and carbon for growth 3, 10 . Such cells use glutamine to supply anaplerosis, the replenishment of CAC intermediates withdrawn from the cycle to feed biosynthetic pathways. Both WT and CYTB 143B cells require glutamine for colony formation, implying a respirationindependent function for glutamine in cell growth 9 , and both cell types consumed glutamine at similar rates ( Fig. 1a ). We cultured both cell lines with L[U-13 C]glutamine to define the metabolic fates of glutamine. Like other glutamine-dependent cancer cells 11 , WT 143B cells used glutamine as the major anaplerotic precursor, resulting in a large amount of fumarate, malate and citrate m14 ( Fig. 1c, d ; Supplementary Figs 1e and 3, top). In contrast, CYTB 143B cells produced only trace quantities of citrate m14. Instead, they produced citrate m15 through reductive carboxylation of glutamine-derived a-ketoglutarate ( Fig. 1c ). This reaction involves addition of an unlabelled carbon by isocitrate dehydrogenase (IDH) acting in reverse relative to the canonical oxidative CAC 12 . Cleavage of citrate m15 by ATP-citrate lyase then produces acetyl-CoA m12 and OAA m13, with the unlabelled carbon retained on OAA ( Supplementary Fig. 3 , bottom). Examination of other CAC metabolites in CYTB 143B cells revealed that they were formed downstream of citrate m15 and OAA m13. These cells contained abundant malate and fumarate m13, which was essentially absent from WT 143B cells ( Fig. 1d and Supplementary Fig. 1e ). Thus these metabolites are generated from reductive, rather than oxidative, glutamine metabolism ( Fig. 1e ). Succinate was formed through both reductive and oxidative glutamine metabolism in CYTB 143B cells ( Supplementary Fig. 1f ). Glutamine-dependent reductive carboxylation was also observed in CYTB 143B cells cultured in medium containing a full complement of amino acids ( Supplementary Fig. 4 ), and in cells with a genetic defect in ETC complex I ( Supplementary Fig. 5 ).
To determine which of the three IDH isoforms contributed to reductive carboxylation, we used RNA interference (RNAi) to silence expression of IDH1 (isocitrate dehydrogenase 1 (NADP 1 ), soluble), IDH2 and IDH3 in CYTB 143B cells and measured glutamine-derived 13 C labelling in citrate. Silencing either of the NADP 1 /NADPHdependent IDH isoforms, IDH1 or IDH2, reduced citrate m15 in cells cultured with L[U-13 C]glutamine and silencing both at once further reduced citrate m15 ( Fig. 2a, b ). Conversion of glutamine to glutamate was unaffected ( Fig. 2b ). Silencing IDH3, the mitochondrial NAD 1 / NADH-dependent isoform, had no effect on labelling ( Fig. 2a, b ). Thus reductive carboxylation in CYTB 143B cells involves IDH1 and IDH2, but not IDH3. Because IDH1 and IDH2 proteins are localized primarily in the cytoplasm and mitochondria, respectively, of both cell lines ( Supplementary Fig. 6 ), the data suggest that reductive carboxylation in CYTB 143B cells may occur in either compartment.
To determine whether IDH1 and IDH2 are required for growth, we stably silenced each enzyme using lentiviral RNAi. In WT 143B cells, silencing either isoform reduced cell growth ( Supplementary Fig. 7 ), consistent with findings in other cancer cells with normal mitochondria 13 . In CYTB 143B cells, a similar growth reduction occurred when either isoform was silenced ( Supplementary Fig. 7 ). Thus both IDH1 and IDH2 support growth in cells that use glutamine-dependent reductive carboxylation.
We next determined whether reductive glutamine metabolism contributed to lipogenesis, a biosynthetic activity required for cancer cell growth. Both WT and CYTB 143B cells produced fatty acids de novo, as indicated by incorporation of 3 H 2 O into lipids (Fig. 3a ). The two cell lines were then cultured with 14 C-labelled lipogenic substrates to examine carbon preferences for lipogenesis ( Fig. 3a ). Both cell lines had an intact pathway of lipogenesis from exogenously supplied acetate. The enhanced labelling in CYTB 143B cells probably resulted from an increased specific activity of the intracellular two-carbon pool because of suppressed PDH. Lipids derived from CYTB 143B cells contained little radioactivity from glucose, but abundant radioactivity from glutamine, indicating a switch in the extent to which these nutrients supplied lipogenesis. To quantify the contribution of glucose and glutamine to lipogenic acetyl-CoA, cells were cultured in medium C]glutamine and unlabelled glucose. Extracted lipids were analysed by 13 C NMR. Because fatty acids are synthesized by the sequential addition of two-carbon units, analysing 13 C-13 C coupling between the v 2 1 and v 2 2 carbons-which enter the fatty acyl chain on different two-carbon units-enables calculation of 13 C enrichment in lipogenic acetyl-CoA 3 . In the v 2 1 multiplet, 13 C-13 C coupling produces a triplet when two 13 C-labelled twocarbon units are added in succession, whereas one labelled and one unlabelled unit produce a doublet (Fig. 3b) . Therefore 13 C labelling in lipogenic acetyl-CoA is proportional to the contribution of the triplet to the overall area of the v 2 1 multiplet. In WT 143B cells cultured with D[U-13 C]glucose, the v 2 1 resonance was dominated by the triplet, which accounted for 65% of the total area (Fig. 3c, left) . Glutamine was a minor source of fatty acyl carbon, as the triplet accounted for only 15% of the area when the cells were cultured with L[U-13 C]glutamine ( Fig. 3d, left) . This pattern was reversed in the CYTB 143B cells, with glutamine providing 67% of the lipogenic carbon ( Fig. 3c, d, right; Supplementary Fig. 8a ). Thus, reductive glutamine metabolism was the major pathway of fatty acid production in newly synthesized lipids during CYTB 143B growth.
Although most cancer cells have functional mitochondria, a subset of human tumours harbours mutations that impair mitochondrial metabolism. Two major classes of mutations occur in genes required for function of the CAC enzymes succinate dehydrogenase (SDHA, SDHB, SDHC, SDHD, SDHAF2) or fumarate hydratase (FH) 14 . To test whether glutamine-dependent reductive carboxylation occurs in tumour cells harbouring these mutations, we studied UOK262 cells derived from a renal tumour in a patient with hereditary leiomyomatosis renal cell carcinoma syndrome. In this syndrome, affected individuals inherit one loss-of-function FH allele and their tumours display loss of heterozygosity for the FH locus 15 . UOK262 cells are defective in respiration and devoid of FH activity 15 . They failed to survive culture in glucosefree medium containing galactose and glutamine (Fig. 4a ), a condition that forces cells to use mitochondrial metabolism to generate ATP 16 . Lack of FH activity precludes the use of glutamine as a carbon source in the conventional oxidative CAC. Yet the UOK262 cells required glutamine to proliferate (Fig. 4b ). Culture of these cells with D[U-13 C]glucose produced mass isotopomer data similar to CYTB 143B cells, with minimal formation of citrate m12 (Fig. 4c, left) . In cells cultured with L[U-13 C]glutamine, the most abundant mass isotopomer of citrate was m15 formed by reductive carboxylation (Fig. 4c, left) . Fumarate was predominantly formed through oxidative glutamine metabolism, producing fumarate m14 (Fig. 4c, middle) . However, a large fraction of the malate pool (m13) was formed via citrate cleavage and subsequent reductive metabolism (Fig. 4c, right) . Lipid labelling using D[U-13 C]glucose or L[U-13 C]glutamine revealed that, like CYTB 143B cells, glutamine is the major carbon source for fatty acid synthesis ( Supplementary Fig. 8b ). Thus these cancer cells produce CAC intermediates using two distinct pathways to compensate for the loss of FH enzyme activity: oxidative metabolism of glutamine to fumarate, and glutamine-dependent reductive carboxylation to produce citrate, acetyl-CoA for lipogenesis and remaining four-carbon CAC intermediates.
Finally, we tested whether glutamine-dependent reductive carboxylation was unique to cells with permanent abnormalities in mitochondrial metabolism. WT 143B cells and transformed mouse embryonic fibroblasts (MEFs) were subjected to acute ETC inhibition. Exposure to inhibitors of complex III (antimycin) or complex I (rotenone) induced a switch from oxidative to reductive metabolism of glutamine ( Fig. 4d,  Supplementary Fig. 9a ). Enhanced reductive carboxylation was evident one hour after ETC inhibition and was not eliminated by pre-treatment with the protein synthesis inhibitor cycloheximide (Supplementary Fig. 9b, c) . Metformin, an antidiabetic agent that inhibits respiration through effects on complex I 17 , also induced glutaminedependent reductive carboxylation at high doses ( Fig. 4d, Supplementary   Fig. 9a ). Interestingly, doses that mimicked plasma concentrations in patients with acute metformin toxicity and lactic acidosis induced reductive glutamine metabolism ( Supplementary Fig. 10 ). These data demonstrate that glutamine-dependent reductive carboxylation is a common cellular response to impaired mitochondrial metabolism.
Glutamine-dependent reductive carboxylation has been described previously as a minor source of isocitrate/citrate and lipogenic carbon in mammalian cells 12, 13, [18] [19] [20] . In Plasmodium falciparum, a unicellular protozoan with limited respiration, the pathway is a major source of citrate and acetyl units 21 . We show that this pathway can also function as the predominant metabolic strategy to produce lipids for cancer cell growth, and can be induced acutely during ETC inhibition. We speculate that reductive carboxylation is stimulated by a disturbance in the redox ratio of the mitochondria caused by ETC impairment, decreasing the NAD 1 /NADH ratio and rendering oxidative function of the CAC less efficient. This ratio could be dissipated in part by NAD(P)transhydrogenases, which transfer reducing equivalents from NADH to NADPH, and this in turn may drive NADPH-dependent reductive carboxylation by IDH1 and IDH2. This redirection of the CAC extends the versatility of glutamine metabolism in cancer cell growth. In cells with normal mitochondria, glutamine oxidation is frequently the major source of anaplerosis, providing most of the carbon to pools of CAC intermediates and facilitating production of macromolecular precursors in the mitochondria 22 . Glutamine-dependent reductive carboxylation enables glutamine to retain this status as a growthpromoting nutrient even when mitochondrial metabolism is impaired. Therefore, during malignant transformation the acquisition of somatic mutations that impair mitochondrial function and stimulate aerobic glycolysis (the Warburg effect) does not diminish the importance of glutamine metabolism or of the mitochondria themselves for tumour cell proliferation. 
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METHODS SUMMARY
WT 143B, CYTB 143B, UOK262, CCL16-B2 and CCL16-NDI1 cells were cultured as described 9, 15, 23 . MEFs were cultured in Dulbecco's modified Eagle medium (DMEM) with 10% fetal bovine serum (FBS, Hyclone), penicillin/streptomycin and 6 mM L-glutamine. Cell growth was monitored in sub-confluent cultures by trypsinizing and counting with a haemacytometer. Glucose, lactate and glutamine were measured as described 24 . Isotopic labelling was performed in DMEM with 10% dialysed FBS supplemented with either 15 mM D[U-13 C]glucose or 2 mM L[U-13 C]glutamine. Aqueous metabolites were analysed using an Agilent 6970 gas chromatograph and an Agilent 5973 mass selective detector. To determine relative metabolite abundance across samples, the area of the total ion current peak for the relevant metabolite was compared to that of an internal standard (2-oxobutyrate) and normalized for protein content. Analysis of 13 C enrichment and mass isotopomer distribution was performed as published 11, 25 . For radioisotope lipid synthesis assays, cells were cultured for 18 h in complete medium supplemented with 3 H 2 O or 14 C tracers (Perkin Elmer). Lipids were extracted and analysed as described 3 . For lipid synthesis experiments using NMR, cells were plated in 10-cm dishes and allowed to proliferate exponentially in medium containing D[U-13 C]glucose and unlabelled glutamine, or unlabelled glucose and L[U-13 C]glutamine until two confluent 15-cm dishes were obtained. Lipids were then extracted and analysed by 13 C NMR as described 3 . Gene silencing was performed using commercial small interfering RNAs (Thermo) directed against IDH1, IDH2 or IDH3. Cells were transfected with DharmaFECT transfection reagent (Thermo) and protein abundance was examined after 72 h using western blots with commercial antibodies (Santa Cruz Biotechnology). Cells were incubated with L[U-13 C]glutamine for two hours before extraction of metabolites for mass isotopomer distribution analysis. Stable silencing used lentiviral shRNAs from the Mission shRNA pLKO.1-puro library (Sigma).
METHODS
Cell culture, growth and viability. WT 143B, CYTB 143B, CCL16-B2, CCL16-NDI1 and UOK262 cells were cultured as described 9, 15, 23 . Mouse embryonic fibroblasts (MEFs) were cultured in Dulbecco's modified Eagle medium (DMEM) with 10% fetal bovine serum (FBS, Hyclone), penicillin/streptomycin and 6 mM L-glutamine. Doubling times were calculated by repeatedly allowing sub-confluent cultures to reach confluence, then trypsinizing, counting and re-plating at low confluence. Nutrient utilization and secretion. Concentrations of glucose, lactate and glutamine in tissue culture medium were measured using a NOVA BioProfile Basic4 chemical analyser as described 24 . Rates of consumption/secretion were calculated by determining the change in metabolite concentration over 6 h, converting this change into nmoles consumed or secreted, and normalizing to protein content. Mass isotopomer distribution and mass spectrometry. Nutrients labelled with 13 C were purchased from Cambridge Isotope Laboratories. All 13 C studies were performed in medium containing 10% dialysed FBS and prepared so that 100% of either the glucose or glutamine pool was labelled with 13 C, and the other pool was unlabelled. DMEM lacking both glucose and glutamine was prepared from powder (Sigma), then supplemented with either 15 mM D[U-13 C]glucose and 2 mM unlabelled glutamine, or 15 mM unlabelled glucose and 2 mM L[U-13 C]glutamine. For experiments with RPMI ( Supplementary Fig. 4 ), we supplemented glutaminefree RPMI (11 mM unlabelled glucose, Invitrogen) with 2 mM L[U-13 C]glutamine. Cells were grown in 60-or 100-mm dishes until 80% confluent, then rinsed with PBS and cultured with 13 C-containing medium for the indicated time (usually 6 h). The cells were then extracted by freeze-thawing three times in 0.5 ml of a cold 1:1 mixture of methanol:water. Macromolecules and debris were removed by centrifugation, an internal standard was added (50 nmol of 2-oxobutyrate), and the supernatants with aqueous metabolites were evaporated completely and derivatized for 30 min at 42 uC in 100 ml of a trimethylsilyl donor (Tri-Sil, Thermo). Metabolites were analysed using an Agilent 6970 gas chromatograph networked to an Agilent 5973 mass selective detector. Retention times and mass fragmentation signatures of all metabolites were validated using pure standards. To determine relative metabolite abundance across samples, the area of the total ion current peak for the metabolite of interest was compared to that of the internal standard and normalized for protein content. The mass isotopomer distribution analysis measured the fraction of each metabolite pool that contained every possible number of 13 C atoms; that is, a metabolite could contain 0, 1, 2, … n 13 C atoms, where n 5 the number of carbons in the metabolite. For each metabolite, an informative fragment ion containing all carbons in the parent molecule was analysed using MSDChem software (Agilent), integrating the abundance of all mass isotopomers from m10 to m1n, where m 5 the mass of the fragment ion without any 13 C. A list of fragment ions is in ref. 11 . The abundance of each mass isotopomer was then corrected mathematically to account for natural abundance isotopes 25 and finally converted into a percentage of the total pool. Lipid synthesis assays. All radioisotopes were from Perkin-Elmer. Culture with 3 H 2 O was used to measure total lipid synthesis by preparing high-glucose DMEM from powder (Sigma) and supplementing with 2 mM L-glutamine and 10% FBS. The 3 H 2 O was added during preparation of this medium to a final content of 21% of the total volume. The 14 C assays also used high-glucose DMEM with 2 mM L-glutamine, 10% FBS and tracer quantities of [1, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]glucose (10 mCi, 1.7 mM) or L[U-14 C]glutamine (10 mCi, 1.9 mM). In all radioisotope assays, cells were grown to 80-90% confluence then cultured for 18 h in medium containing the label. Lipids were then extracted and analysed by scintillation counting as previously described 3 . For 13 C NMR experiments, cells were plated at approximately 50% confluence in 10-cm dishes and allowed to proliferate exponentially in complete DMEM containing either 15 mM D[U-13 C]glucose and 2 mM unlabelled glutamine, or 15 mM unlabelled glucose and 2 mM L[U-13 C]glutamine until two confluent 15-cm dishes were obtained. Glucose and glutamine concentrations were monitored in the medium to ensure that neither nutrient was depleted during expansion of the culture. Lipids were then extracted and analysed by 13 C NMR as described 3 using a Varian ANOVA 14.1 T spectrometer equipped with a 3-mm broadband probe with the observe coil tuned to 13 C (150 MHz). Relevant peak areas were determined using ACDLabs SpecManager (Advanced Chemistry Development). RNA interference. Transient gene silencing experiments were performed using commercial siRNA pools (siGENOME, Thermo) directed against IDH1, IDH2, IDH3 (catalogue numbers MU-008294-00, MU-004013-00 and MU-008753-00, respectively). For the simultaneous silencing of IDH1 and IDH2, individual siRNAs rather than pools were used (IDH1: 59-GGACUUGGCUGCUUGC AUU-39; IDH2: 59-CAAGAACUAUGACGGAGAU-39). Cells were transfected with DharmaFECT transfection reagent (Thermo), and protein abundance was examined after 72 h using western blots with commercial antibodies against IDH1, IDH2 or IDH3 (Santa Cruz Biotechnology). Cells were incubated with L[U-13 C]glutamine for two hours before extraction of metabolites for mass isotopomer distribution analysis. Stable silencing used lentiviral-mediated shRNAs from the Mission shRNA pLKO.1-puro library (Sigma). Cells were infected with each lentivirus using the manufacturer-supplied protocol, and pools of puromycin-resistant cells were used for subsequent experiments. Pools with the best silencing of IDH1 or IDH2 were used in the growth assay. Subcellular localization studies. WT 143B and CYTB 143B cells were transfected with siRNA as described above. After 72 h, the transfected cells were incubated in medium containing 1 mM Mitotracker Deep Red FM (Invitrogen) for 30 min. The cells were then fixed with 3.7% formaldehyde in PBS for 15 min, permeabilized with 0.5% (v/v) Triton X-100 for 5 min, and blocked with 1% bovine serum albumin for 5 min. Immunofluorescence used commercial antibodies against IDH1 (Santa Cruz Biotechnology) or IDH2 (Abcam) followed by anti-goat or anti-mouse secondary antibodies conjugated to Alexa Fluor-488. Cells were stained with primary and secondary antibodies for one hour at room temperature and mounted on Vectashield mounting medium containing DAPI (Vector Laboratories). Images were acquired using an LD Plan-Neofluar 403/1.3 DIC objective on a Zeiss Axioplan 2E imaging deconvolution microscope. Mitochondrial fractions were isolated by differential centrifugation as previously described 26 .
